Scholarlink

Purpose <p>To compare the efficacy and safety of one-site versus two-site phacotrabeculectomy in the management of concurrent cataract and glaucoma through an updated systematic review and meta-analysis of randomized controlled trials.</p> Methods <p>Systematic searches were conducted across seven electronic databases through February 2025. Only randomized controlled trials comparing one-site versus two-site phacotrabeculectomy were included. Primary outcome was intraocular pressure (IOP) reduction. Secondary outcomes included anti-glaucoma medication (AGM) use, visual acuity, endothelial cell loss, and complications. Meta-regression analyzed the effects of mitomycin C (MMC) usage, age, and follow-up duration on outcomes.</p> Results <p>Sixteen randomized controlled trials (1087 eyes) were included. Both techniques achieved comparable IOP reduction at most timepoints. Although two-site surgery demonstrated a trend toward greater IOP reduction at select intervals (e.g., day one and 18 months), these differences were not statistically significant. AGM requirements were similar between groups at 12 months (mean difference: 0.05; 95% CI − 0.16, 0.27). Visual outcomes were comparable, though influenced by age (<i>p</i> = 0.004) and MMC use (<i>p</i> = 0.025). Endothelial cell loss was initially greater with two-site surgery but stabilized over time. Complication rates, including hyphema (OR: 0.99; 95% CI: 0.56, 1.76) and bleb-related complications (OR: 1.09; 95% CI 0.55, 2.16), were similar between groups.</p> Conclusions <p>One-site and two-site phacotrabeculectomy demonstrate comparable efficacy and safety profiles. While two-site surgery shows a trend toward greater IOP reduction, the differences are not clinically significant. Surgical approach should be individualized based on patient characteristics, surgeon experience, and specific surgical goals rather than assumed superiority of either technique.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The comparative efficacy and safety of one-site versus two-site phacotrabeculectomy: an updated systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年11月12日

查看全文
  • Abdelaziz Abdelaal,
  • Husam Abu Suilik,
  • Abdullah Ahmed,
  • Shrouk F. Mohamed,
  • Ahmed Sermed Al Sakini,
  • Mahmoud Elgazzar,
  • Ahmed Atif Elswaf,
  • Belal Shehata,
  • Bara Al Sharief,
  • Basant Katamesh,
  • Abdulmajid Makki,
  • Rahma Sameh Shaheen,
  • Mostafa Mahmoud Naguib,
  • Hashem Abu Serhan

摘要

Purpose

To compare the efficacy and safety of one-site versus two-site phacotrabeculectomy in the management of concurrent cataract and glaucoma through an updated systematic review and meta-analysis of randomized controlled trials.

Methods

Systematic searches were conducted across seven electronic databases through February 2025. Only randomized controlled trials comparing one-site versus two-site phacotrabeculectomy were included. Primary outcome was intraocular pressure (IOP) reduction. Secondary outcomes included anti-glaucoma medication (AGM) use, visual acuity, endothelial cell loss, and complications. Meta-regression analyzed the effects of mitomycin C (MMC) usage, age, and follow-up duration on outcomes.

Results

Sixteen randomized controlled trials (1087 eyes) were included. Both techniques achieved comparable IOP reduction at most timepoints. Although two-site surgery demonstrated a trend toward greater IOP reduction at select intervals (e.g., day one and 18 months), these differences were not statistically significant. AGM requirements were similar between groups at 12 months (mean difference: 0.05; 95% CI − 0.16, 0.27). Visual outcomes were comparable, though influenced by age (p = 0.004) and MMC use (p = 0.025). Endothelial cell loss was initially greater with two-site surgery but stabilized over time. Complication rates, including hyphema (OR: 0.99; 95% CI: 0.56, 1.76) and bleb-related complications (OR: 1.09; 95% CI 0.55, 2.16), were similar between groups.

Conclusions

One-site and two-site phacotrabeculectomy demonstrate comparable efficacy and safety profiles. While two-site surgery shows a trend toward greater IOP reduction, the differences are not clinically significant. Surgical approach should be individualized based on patient characteristics, surgeon experience, and specific surgical goals rather than assumed superiority of either technique.